A comprehensive analysis of the functions, efficacy and indications of Ixazomib (Enleri)

Ixazomib is an oral proteasome inhibitor that blocks the protein degradation pathway of cancer cells by inhibiting the activity of the 26S proteasome, leading to the accumulation of abnormal proteins in cells and triggering tumor cell apoptosis. Compared with traditional intravenous proteasome inhibitors, the oral dosage form of ixazomib is convenient for patients to self-administer in the long term and can exert a synergistic anti-tumor effect in combination chemotherapy regimens.

Ixazomib interferes with the proteostasis of tumor cells by reversibly inhibiting proteasome activity, inducing cellular stress responses and activating apoptotic pathways. At the same time, it can inhibit growth-promoting signals in the tumor microenvironment and reduce the proliferation ability of tumor cells. It specifically acts on cancer cells, causing less damage to normal cells, and has certain selectivity and safety advantages.

Clinical studies have shown that ixazomib has significant efficacy in patients with multiple myeloma (MM) and can improve the response rate, prolong progression-free survival (PFS) and overall survival (OS). Antitumor activity can be further enhanced when used in combination with rituximab or lenalidomide. In patients with relapsed or refractory multiple myeloma, ixazomib also shows good efficacy and tolerability, improving patients' quality of life.

Ixazomib is suitable for adult patients with multiple myeloma, especially those with relapsed or refractory disease, and can also be used in combination regimens for initially treated patients. During use, individualized dosage adjustments must be made based on the patient's liver and kidney function, hematological indicators, and previous medication history. Through scientific use and optimization of combination regimens, ixazomib can improve efficacy while taking into account safety, providing long-term management and treatment options for patients with multiple myeloma.

Reference materials:https://www.drugs.com/